Labiana strengthens its corporate governance with the appointment of Carme Hortalà and Juan Ortiz as new Board members
- The pharmaceutical company formalized both appointments at the General Shareholders’ Meeting held today in Madrid.
Madrid, June 26, 2025 – Labiana, the pharmaceutical company specializing in animal and human health listed on BME Growth, is reinforcing its corporate governance with the appointment of Carme Hortalà as a new independent director and Juan Ortiz as a new proprietary director. Both appointments were endorsed by the group’s Appointments and Remuneration Committee.
Carme Hortalà holds a degree in Economics from the University of Barcelona and is a certified financial analyst by the Spanish Institute of Financial Analysts. She brings over 40 years of experience in the financial sector. Much of her career has been linked to GVC Gaesco, where she currently serves as General Director of Corporate Development, after previously leading the commercial division and serving as CEO of the financial group.
Carme is also an independent director at the telecommunications operator Parlem, a position she has held for two years, and at the Catalan Institute of Finance (ICF) for just over a year. Since 2021, she has also been a member of the Economic Commission of FC Barcelona.
Carme Hortalà joins Labiana to contribute her solid and proven experience in the financial services sector, particularly in the impartial and strategic oversight of management, the protection of shareholder interests, regulatory compliance, and in enhancing the quality and transparency of financial reporting.
Juan Ortiz holds a Law degree with a focus on Business Management from CEU Luis Vives University. He has spent most of his career at Suanfarma, holding various roles from Area Manager for LATAM and North Africa to Global General Manager of Pharma.
Juan joins Labiana to contribute his experience and expertise in the pharmaceutical sector to the group’s business management, planning, control, and strategic development, while also bringing his skills in the evaluation and management of highly qualified human resources.
At the General Shareholders’ Meeting, Labiana CEO Manuel Ramos emphasized that “these appointments were previously endorsed by the analysis of the group’s Appointments and Remuneration Committee, which highlights their professional background, training, and capabilities to drive Labiana’s business model and strategic growth plan.”
About Labiana
Labiana Health is an independent, integrated international leader in animal and human health, with a diversified portfolio of products and businesses and a broad client base of top-tier companies with long-lasting relationships built on trust. It has subsidiaries in Spain, Serbia, Turkey, and Mexico, with production centers distributed between Spain and Serbia. Labiana’s products are present in over 150 markets, with product registrations in more than 90 countries. The group has two differentiated and complementary business lines: contract manufacturing in both veterinary and human health, which provides stability and income visibility, and the development, manufacturing, and commercialization of its own products in both animal and human health, driving growth. The company debuted on BME Growth in June 2022, becoming the first veterinary company to list on Spain’s BME Growth Market.
FORWARD-LOOKING STATEMENTS
This communication may contain information and forward-looking statements or declarations regarding LABIANA. It may also include financial projections and/or estimates with their underlying assumptions, statements concerning plans, objectives, and expectations regarding future operations, investments, synergies, products, and services, as well as statements about future results. Forward-looking statements are not historical facts and are generally identified by the use of terms such as “expects,” “anticipates,” “believes,” “intends,” “estimates,” and similar expressions.
While LABIANA believes that the expectations reflected in such statements are reasonable, investors and shareholders of LABIANA are cautioned that forward-looking information and statements are subject to risks and uncertainties, many of which are difficult to predict and are generally beyond the control of LABIANA. These factors could cause actual results and developments to differ significantly from those expressed, implied, or projected in the forward-looking information and statements.
Such risks and uncertainties include those identified in documents submitted by LABIANA to BME Growth, which are publicly accessible. It is recommended not to make decisions based on forward-looking statements, as they refer solely to the date on which they were made, do not constitute a guarantee of future results, and have not been audited by LABIANA’s auditors.
All forward-looking statements or declarations, whether oral or written, made by LABIANA or any of its board members, executives, employees, or representatives are expressly subject to these warnings. The forward-looking statements or declarations included in this document are based on the information available to LABIANA as of the date of this communication.
Leave a Comment